Emisphere Tech (EMIS) 0.4898 $EMIS Emisphere

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Emisphere Tech (EMIS) 0.4898 $EMIS

Emisphere Technologies' (EMIS) CEO Alan Rubino on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri May 15, 1:10PM CDT


Emisphere Reports First Quarter 2015 Financial Results
GlobeNewswire - Fri May 15, 7:00AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) today reported financial results for the first quarter ended March 31, 2015, and provided an overview of corporate accomplishments and plans.

Emisphere Announces First Quarter 2015 Financial Results Conference Call
GlobeNewswire - Mon May 11, 3:15PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Friday, May 15, 2015, at 8:30 AM EDT to discuss the Company's financial and operational results for the quarter ended March 31, 2015.

Emisphere Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 6:50AM CDT
Recent Launch of Eligen B12(TM) Marks Company's Expansion into Commercializing Practical Innovation

Emisphere Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call
GlobeNewswire - Wed Mar 25, 3:20PM CDT
Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that management will host a conference call on Tuesday, March 31, 2015, at 8:30 AM ET to discuss the Company's financial and operational results for the quarter and twelve months that ended December 31, 2014.

Key Aspects Of A Potential Novo Nordisk Oral GLP-1 Phase 3 Trial
PLM Investments - at Seeking Alpha - Fri Mar 20, 10:52AM CDT

NVO: 56.75 (+0.06)

Penny Stocks Alerts for Sabine Oil & Gas, HDS International, Integral Technologies, Quicksilver Resources, FLEXPOWER, and Emisphere
PR Newswire - Thu Mar 19, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Sabine Oil & Gas (OTCMKTS:SOGC), HDS International (OTCMKTS:HDSI), Integral Technologies (OTCMKTS:ITKG), Quicksilver Resources (OTCMKTS:KWKA), FLEXPOWER (OTCMKTS:FLXP), and Emisphere Technologies (OTCMKTS:EMIS).

Emisphere Launches Eligen B12(TM), the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection
PR Newswire - Thu Mar 19, 7:15AM CDT
Emisphere Technologies, Inc. (OTCBB: EMIS) today announced the U.S. commercial availability of Eligen B12(TM), the first and only once-daily oral prescription medical food tablet shown to normalize B12 levels without the need for an injection. Eligen B12 is indicated for the dietary management of patients who have a medically-diagnosed vitamin B12 deficiency, associated with a disease or condition that cannot be managed by a modification of the normal diet alone.

Novo Nordisk Is In The NASH Space, Too
PLM Investments - at Seeking Alpha - Wed Mar 18, 6:52PM CDT

NVO: 56.75 (+0.06), GILD: 109.30 (+0.56), ICPT: 306.23 (-0.84)

Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
PLM Investments - at Seeking Alpha - Thu Feb 19, 10:25AM CST

NVO: 56.75 (+0.06)

Emis Group's (EMIS) CEO Alan Rubino on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:25PM CST


Emisphere Tech Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:13AM CST


Emisphere Technologies EPS of -$0.24
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 7:36AM CST


Emisphere Technologies Announces Financial Results for the Third Quarter 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced its financial results for the quarter ended September 30, 2014. The Company will host a conference call this morning at 8:30 AM ET to discuss these results.

Emisphere reports November 14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:34AM CST


Emisphere Technologies Announces Third Quarter 2014 Earnings Conference Call
GlobeNewswire - Wed Nov 12, 7:00AM CST
Emisphere Technologies, Inc. (OTCQB:EMIS) (the "Company" announced today that Management will host a conference call to discuss the Company's financial and operational results for the three months ended September 30, 2014 on Friday, November 14, 2014 at 8:30 AM ET. A press release will be issued prior to market opening.

Emisphere enters into USD20m debt financing to introduce oral Eligen B12 in the US market
M2 - Thu Aug 21, 7:31AM CDT
Pharmaceutical company Emisphere Technologies (OTC BB:EMIS) reported on Wednesday the execution of new loan facility agreement to finance the upcoming launch of its first commercial prescription product oral Eligen B12 in the US for B12 deficient individuals.

Emisphere Announces $20 Million Debt Financing to Launch Oral Eligen(R) B12
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Emisphere Technologies, Inc. (OTCBB:EMIS) ("Emisphere" or the "Company" today announced that it has reached agreement with MHR Fund Management LLC, and certain of its affiliated funds ("MHR" , to finance the upcoming launch of the Company's first commercial prescription product, oral Eligen B12 in the United States through a new loan facility, and to amend the terms of the Company's existing obligations under various promissory notes previously issued to MHR to extend the maturity dates of such promissory notes.

Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 56.75 (+0.06), ORMP: 6.51 (+0.07), TTHI: 6.69 (+0.02), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alliance for Women in Media Champions Change in 2026

Updated Category News Views 87

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 141

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 120

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 124

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 61

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 23

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 199

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Formula Wellness Scores Top 50 Position from Allergan

Updated Category News Views 15

Pushing Boundaries in Aesthetic and Wellness Here's something you don't see every day: Formula Wellness just landed Top 50 status for 2026 from Allergan Aesthetics, the same folks who brought Botox to the world. It’s no small feat, and if you've been keeping an eye on sectors blending wellness with aesthetics, this might be the story to watch. Formula Wellness isn't...

Continue Reading
iTeos Therapeutics Showcases Inupadenant Trial Insights at ESMO

Updated Category News Views 98

Introduction to iTeos Therapeutics and ESMO Congress iTeos Therapeutics, Inc. (NASDAQ: ITOS), based in Watertown, Mass. and Gosselies, Belgium, is making strides in the field of biopharmaceuticals. Their mission focuses on pioneering a new wave of immuno-oncology therapies aimed at fighting cancer. The excitement around their innovative approaches is palpable, especially...

Continue Reading
Plastic vs. Metal Parts: The Manufacturing Showdown

Updated Category News Views 65

Understanding the Material Dilemma In manufacturing, a pivotal choice emerges early on: plastic or metal? It's a game-changer in product development, according to Ryan Eggleston from UTP Solutions. The stakes are high because picking the right material can define the success—or failure—of a product design. The Rise of Plastics Plastics have carved out a strong niche...

Continue Reading
Fast Debt Recovery Specialist Sets New Standards in Compliance

Updated Category News Views 105

Fast Debt Recovery Specialist Earns Newly Required License Fast Debt Recovery Specialist has marked a major milestone, becoming one of the first firms in Singapore to secure the government’s newly required debt collection license. It’s a clear signal: the agency intends to operate squarely within the law while holding fast to ethical, transparent recovery practices....

Continue Reading
Rivian's 2024 Performance: Impressive Production and Delivery Stats

Updated Category News Views 327

Rivian Announces Strong Production and Delivery Figures for 2024 Rivian Automotive, Inc. (NASDAQ: RIVN), a leading player in the electric vehicle market, has revealed its impressive production and delivery totals for 2024. The company successfully produced a remarkable 12,727 vehicles in the fourth quarter alone, rounding off a total annual production of 49,476 vehicles....

Continue Reading